The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")

Pharmacological Reviews

Volumn 55, Issue 3, 2003, Pages 463-508

  Green, A Richard ^a,b   Mechan, Annis O ^a,d   Elliott, J Martin ^a   O'Shea, Esther ^c   Colado, M Isabel ^c  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE DERIVATIVE; BRAIN MONOAMINE; CHLORAMPHETAMINE; DOPAMINE; FENFLURAMINE; FREE RADICAL; MESCALINE; METHAMPHETAMINE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; BEHAVIOR; BODY TEMPERATURE; BRAIN BLOOD FLOW; BRAIN FUNCTION; CARDIOVASCULAR EFFECT; CLINICAL PHARMACOLOGY; COGNITION; COGNITIVE DEFECT; CULTURAL ANTHROPOLOGY; DANCING; DEGENERATIVE DISEASE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; FOREBRAIN; GENE INDUCTION; HUMAN; HYPERACTIVITY; HYPERTHERMIA; IMMEDIATE EARLY GENE; IMMUNE RESPONSE; LOCOMOTION; MENTAL DISEASE; MOTOR PERFORMANCE; MOUSE; MULTIPLE DRUG ABUSE; NERVE DEGENERATION; NERVE ENDING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; PRENATAL DRUG EXPOSURE; PREPULSE INHIBITION; PRIMATE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RAT; RECEPTOR DENSITY; REINFORCEMENT; REVIEW; RODENT; SELF STIMULATION; SEROTONIN BEHAVIOR SYNDROME; SEROTONIN RELEASE; SEROTONIN SYNDROME; STARTLE REFLEX; SYMPATHETIC TONE; TISSUE INJURY;

ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BRAIN; DOPAMINE; FREE RADICALS; HALLUCINOGENS; HUMANS; HYPERKINESIS; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURODEGENERATIVE DISEASES; NOREPINEPHRINE; PRIMATES; RATS; SEROTONIN; TIME FACTORS;

EID: 0041466261     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.55.3.3     Document Type: Review

References (414)

1. 1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol 346:181-188.
2. Aguirre N, Barrionuevo M, Lasheras B, and Del Rio J (1998b) The role of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxyamphetamine-induced neurotoxicity in rats. J Pharmacol Exp Ther 286:1159-1165.
3. Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, and Lasheras B (1999) Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 10:3675-3680.
4. 1A receptors in rats. Eur J Pharmacol 281:101-105.
5. Ali SF and Itzhak Y (1998) Effects of 7-nitroindazole, an NOS inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice. Ann NY Acad Sci 844:122-130.
6. Al-Sahli W, Ahman H, Kheradmand F, Connolly C, and Docherty JR (2001) Effects of methylenedioxymethamphetamine on noradrenaline-evoked contractions of rat right ventricle and small mesenteric artery. Eur J Pharmacol 422:169-174.
7. Angel I, Taranger MA, Claustre Y, Scatton B, and Langer SZ (1988) Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. Life Sci 43:651-658.
8. Askew BM (1961) Amphetamine toxicity in aggregated mice. J Pharm Pharmacol 13:701-703.
9. Aston JC, Beveridge TJR, and Elliott JM (2002) MDMA induces localised increases in arc mRNA expression in rat brain in a dose-dependent fashion. Br J Pharmacol 134:65P
10. Aston JC and Elliott JM (2002) Paroxetine modulates the expression of the immediate early gene arc induced by MDMA in rat brain. Br J Pharmacol 135:346P.
11. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, and Varner KJ (2002) Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of ecstasy. J Pharmacol Exp Ther 302:898-907.
12. Bai F, Jones DC, Lau SS, and Monks TJ (2001) Serotonergic neurotoxicity of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)-methylenedioxymethamphetamine (Ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase. Chem Res Toxicol 14:863-870.
13. Bai F, Lau SS, and Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxymethamphetamine-mediated neurotoxicity. Chem Res Toxicol 12:1150-1157.
14. 2 receptors. Neuropsychopharmacology 26:140-152.
15. Barrett PJ and Taylor GT (1993) "Ecstasy" ingestion: a case report of severe complications. J R Soc Med 86:233-234.
16. Battaglia G, Brooks BP, Kulsakdinun C, and De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163.
17. Battaglia G, Sharkey J, Kuhar MJ, and De Souza EB (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine) assessment using quantitative autoradiography. Synapse 8:249-260.
18. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916.
19. Battaglia G, Zaczek R, and De Souza EB (1990) MDMA effects in brain: pharmacologic profile and evidence of neurotoxicity from neurochemical and autoradiographic studies, in Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA (Peroutka SJ ed) pp 171-190, Kluwer Academic Publishers, Norwalk, MA.
20. Bendotti C, Baldessari S, Pende M, Tarizzo G, Miari A, Presti ML, Mennini T, and Samanin R (1994) Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat? Brain Res Bull 34:389-394.
21. Berger UV, Gu XF, and Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215:153-160.
22. Bhattachary S and Powell JH (2001) Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or "ecstasy": evidence for cognitive impairment. Psychol Med 31:647-658.
23. Bhattacharya SK, Bhattacharya A, and Ghosal S (1998) Anxiogenic activity of methylenedioxymethamphetamine (ecstasy) - an experimental study. Biog Amines 14:217-237.
24. Biello SM and Dafters RI (2001) MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro. Brain Res 920:202-209.
25. Bolla KI, McCann UD, and Ricaurte GA (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51:1532-1537.
26. Boot BP, Mechan AO, McCann UD, and Ricaurte GA (2002) MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol 453:239-244.
27. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, et al. (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98:8966-8967.
28. Braff DL, Geyer MA, and Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups and pharmacological studies. Psychopharmacology 156:234-258.
29. Braida D and Sala M (2002) Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 136:1089-1092.
30. Broening HW, Bacon L, and Slikker W Jr (1994) Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 271:285-293.
31. Broening HW, Bowyer JF, and Slikker W Jr (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275:325-333.
32. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, and Vorhees CV (2001) 3,4-Methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228-3235.
33. Bronstein DM and Hong J-S (1995) Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J Pharmacol Exp Ther 274:943-950.
34. Brown C and Osterloh J (1987) Multiple severe complications from recreational ingestion of MDMA ("Ecstasy"). J Am Med Assoc 258:780-781.
35. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, et al. (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181-1188.
36. Burns N, Olverman HJ, Kelly PA, and Williams BC (1996) Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. Endocr Res 2:601-606.
37. Byrne T, Baker LE, and Poling A (2000) MDMA and learning: effects of acute and neurotoxic exposure in the rat. Pharmacol Biochem Behav 66:501-508.
38. Cadet JL, Ladenheim B, Baum I, Carlson E, and Epstein C (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res 655:259-262.
39. Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E, Epstein C, and Moran TH (1995) Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21:169-176.
40. Cadet J-L, Thiriet N, and Jayanthi S (2001) Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Interne 152:1S57-1S59.
41. Callahan BT, Cord BJ, and Ricaurte GA (2001) Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40:113-121.
42. Callahan BT and Ricaurte GA (1998) Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. Neuroreport 9:2691-2695.
43. Callaway CW, Wing LL, and Geyer MA (1990) Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254:456-464.
44. Camarero J, Sanchez V, O'Shea E, Green AR, and Colado MI (2002) Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81:961-972.
45. Cannon DM, Keenan AK, Guiry PJ, Buon C, Baird AW, and McBean GJ (2001) In vitro neuronal and vascular responses to 5-HT in rats chronically exposed to MDMA. Br J Pharmacol 134:1455-1460.
46. Carvalho M, Carvalho F, Remiao F, Pereira ML, Pires-das-Neves R, and Bastos ML (2002) Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76:166-172.
47. Chadwick IS, Linsley A, Freemont AJ, and Doran B (1991) Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 84:371.
48. Chance MRA (1946) Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J Pharmacol Exp Ther 87:214-219.
49. Chance MRA (1947) Factors influencing the toxicity of sympathomimetic amines to solitary mice. J Pharmacol Exp Ther 89:289-296.
50. 1H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") users. J Magn Reson Imaging 10:521-526.
51. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, and Poland RE (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 98:15-28.
52. Charney DS, Heninger GR, Reinhard JF, Sternberg DE, and Hafstead KM (1982) The effect of IV L-tryptophan on prolactin, growth hormone and mood in healthy subjects. Psychopharmacology 78:38-43.
53. Che S, Johnson M, Hanson GR, and Gibb JW (1995) Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity. Eur J Pharmacol 293:447-453.
54. Christophersen AS (2000) Amphetamine designer drugs - an overview and epidemiology. Toxicol Lett (Shannon) 112-113:127-131.
55. Chu T, Kumagai Y, Distefano EW, and Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796.
56. Cohen RS (1998) The Love Drug. Marching to the Beat of Ecstasy, Haworth Medical Press, Binghamton, NY.
57. Cohen Z, Bonvento G, Lacombe P, and Hamel E (1996) Serotonin in the regulation of brain microcirculation. Prog Neurobiol 50:335-362.
58. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, and Green AR (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on dopamine neurones in mouse brain. Br J Pharmacol 134:1711-1723.
59. Colado MI, Esteban B, O'Shea E, Granados R, and Green AR (1999c) Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration. Psychopharmacology 142:421-425.
60. Colado MI, Granados R, O'Shea E, Esteban B, and Green AR (1998) Role of hyperthermia in the protective action of chlomethiazole against MDMA ("ecstasy")-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. Br J Pharmacol 194:479-484.
61. Colado MI and Green AR (1994) A study of the mechanism of MDMA ("Ecstasy")-induced neurotoxicity of 5-HT neurons using chlormethiazole, dizocilpine and other protective compounds. Br J Pharmacol 111:131-136.
62. Colado MI and Green AR (1995) The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents "ecstasy"-induced neurodegeneration of 5-hydroxytryptamine neurons. Eur J Pharmacol 280:343-346.
63. Colado MI, Murray TK, and Green AR (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108:583-589.
64. Colado MI, O'Shea E, Esteban B, Granados R, and Green AR (1999b) In vivo evidence against chlomethiazole being neuroprotective against MDMA ("ecstasy")-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology 38:307-314.
65. Colado MI, O'Shea E, Granados R, Esteban B, Martín AB, and Green AR (1999a) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") administration. Br J Pharmacol 126:911-924.
66. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, and Green AR (1997b) A study of the neurotoxic effect of MDMA ("ecstasy") on 5-HT neurons in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827-833.
67. Colado MI, O'Shea E, Granados R, Murray TK, and Green AR (1997a) In vivo evidence for free radical involvement in 5-HT following administration of MDMA ("ecstasy") and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121:889-900.
68. Colado MI, Williams JL, and Green AR (1995) The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281-1289.
69. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, and Seiden LS (1987) Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338-345.
70. Connor TJ, McNamara MG, Finn D, Currid A, O'Malley M, Redmond AM, Kelly JP, and Leonard BE (1998) Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology 38:253-260.
71. Connor TJ, McNamara MG, Kelly JP, and Leonard BE (1999) 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat. Hum Psychopharmacol 14:95-104.
72. Craig AL and Kupferberg HJ (1972) Hyperthermia and d-amphetamine toxicity in aggregated mice of different strains. J Pharmacol Exp Ther 180:616-624.
73. Creighton FJ, Black DL, and Hyde CE (1991) "Ecstasy" psychosis and flashbacks. Br J Psychiatry 159:713-715.
74. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylenedioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735-1743.
75. Croft RJ, Mackay AJ, Mills ATD, and Gruzelier JGH (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153:373-379.
76. Curran HV and Travill RA (1997) Mood and cognitive effects of ±-3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): week-end "high" followed by midweek low. Addiction 92:821-831.
77. Dafters RI (1994) Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology 114:505-508.
78. Dafters RI (1995) Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption and chronic dosing. Physiol Behav 58: 877-882.
79. Dafters RI, Duffy F, O'Donnell PJ, and Bouquet C (1999) Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology 145:82-90.
80. Dafters RI and Lynch E (1998) Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") but not by fenfluramine. Psychopharmacology 138:207-212.
81. Darvesh AS, Shankaran M, and Gudelsky GA (2002) 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J Pharmacol Exp Ther 300:138-144.
82. Davison D and Parrott AC (1997) Ecstasy (MDMA) in recreationa) users: selfreported psychological and physiological effects. Human Psychopharmacol 12: 221-226.
83. de la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, Segura J, and Camí J (2000a) Non-linear pharmacokinetics of MDMA ("ecstasy") in humans. Br J Clin Pharmacol 49:104-109.
84. de la Torre R, Farré M, Roset PN, Hernándes-Lópes C, Mas M, Ortuño J, Menoyo E, Pizzarro N, Segura J, and Cami J (2000b) Pharmacology of MDMA in humans. Ann NY Acad Sci 914:225-237.
85. De Souza I, Kelly JP, Harkin AJ, and Leonard BE (1997) An Appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol Toxicol 80:207-210.
86. Dowling GP, McDonough ET III, and Bost RO (1987) "Eve" and "Ecstasy." A report of five deaths associated with the use of MDEA and MDMA. J Am Med Assoc 257:1615-1617.
87. Dragunow M, Logan B, and Laverty R (1991) 3,4-Methylenedioxymethamphetamine induces Fos-like proteins in rat basal ganglia: reversal with MK 801. Eur J Pharmacol 206:255-258.
88. Dulawa SC and Geyer MA (2000) Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology 39:2170-2179.
89. 2C receptors. Psychopharmacology 136:409-414.
90. Erdtmann-Vourliotis M, Mayer P, Riechert U, and Hollt V (1999) Acute injection of drugs with low addictive potential (delta(9)-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine). Mol Brain Res 71:313-324.
91. Esteban B, O'Shea E, Camarero J, Green AR, and Colado MI (2001) 3,4-methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154:251-260.
92. Falk EM, Cook VJ, Nichols DE, and Sprague JE (2002) An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav 72:617-622.
93. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, and Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 45:1058-1069.
94. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, and Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161:356-364.
95. Farfel GM and Seiden LS (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther 272:860-867.
96. Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, and Langston JW (1988) Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res 447:141-144.
97. Fischer C, Hatzidimitriou G, Wlos J, Katz J, and Ricaurte G (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)-3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurosci 15:5476-5485.
98. Fitzgerald RL, Blanke RV, and Poklis A (1990) Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine. Chirality 2:241-248.
99. Fitzgerald JL and Reid JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191:217-220.
100. Fitzgerald JL and Reid JJ (1993) Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn-Schmiedeberg's Arch Pharmacol 347:313-323.
101. Fitzgerald JL and Reid JJ (1994) Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J Pharm Pharmacol 46:826-832.
102. Fone KCF, Beckett SRG, Topham IA, Swettenham J, Ball M, and Maddocks L (2002) Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159:437-444.
103. Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan AD, and Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor? J Pharm Pharmacol 53:1357-1363.
104. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman, AT, and Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135:649-656.
105. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, and Sahakian BJ (2002) Neuropsychological evidence of relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") poly-drug users. Psychopharmacology 162:203-214.
106. Fox HC, Parrott AC, and Turner JJD (2001) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 16:273-281.
107. Frederick DL, Ali SF, Gillam MP, Gossett J, Slikker W, and Paule MG (1998) Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment. Ann NY Acad Sci 44:183-190.
108. Frederick DL, Ali SF, Slikker W Jr, Gilliam MP, Allen RR, and Paule MG (1995) Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatments in rhesus monkeys. Neurotoxicol Teratol 17:531-541.
109. Frederick DL and Paule MG (1997) Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 21:67-78.
110. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, and Vollenweider FX (2001) Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Hum Brain Mapp 14:152-165.
111. 15O]-PET in healthy humans. Neuropsychopharmacology 23:388-395.
112. Gartside SE, McQuade R, and Sharp T (1996) Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J Pharmacol Exp Ther 279:277-283.
113. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi GF, Delsignore R, and Brambilla F (2000) Long-lasting effects of (±)3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans. Biol Psychiatry 47:127-136.
114. Gerra G, Zaimovic A, Guicastro G, Maestri D, Monica C, Sartori R, Caccavari R, and Delsignore R (1998) Serotonergic function after (±) 3,4-methylene-dioxymethamphetamine ("Ecstasy") in humans. Int Clin Psychopharmacol 13:1-9
115. Globus MY-T, Busto R, Lin B, Schnippering H, and Ginsberg MD (1995) Detection of free radical formation during transient global ischemia and recirculation: effects of intraischemic brain temperature modulation. J Neurochem 65:1250-1256.
116. Gold LH, Hubner CB, and Koob GF (1989) A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology 99:40-47.
117. Gold LH and Koob GF (1988) Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol Biochem Behav 29:645-648.
118. Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, Leakey JEA, Kolta M, and Slikker W Jr (1989) Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10:455-466.
119. 2 receptors. Br J Pharmacol 84:743-753.
120. Gordon CJ and Fogelson L (1994) Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire-screen cages: implications for pharmacological studies. Physiol Behav 56:73-79.
121. Gordon CJ, Watkinson WP, O'Callaghan JP, and Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38:339-344.
122. Gough B, Ali SF, Slikker W Jr, and Holson RR (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39:619-623.
123. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Plez S, Becker S, Kunert HJ, Fimm B, and Sass H (2000) Impaired cognitive performance in drug-free recreational Ecstasy (MDMA) users. J Neurol Neurosurg Psychiatry 68:719-725.
124. Grahame-Smith DG (1971a) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18:1053-1066.
125. Grahame-Smith DG (1971b) Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine inhibitor. Br J Pharmacol 43:854-864.
126. Granoff MI and Ashby CR (1998) The effect of the repeated administration of the compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5-HT2A, C receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Neuropsychobiology 37:36-40.
127. Granoff MI and Ashby CR (2001) Effect of the repeated administration of (+/-)-3,4-methylenedioxymethamphetamine on the behavioral response of rats to the 5-HT1A receptor agonist (+/-)-8-hydroxy-(di-n-propylamino)tetralin. Neuropsychobiology 43:42-48.
128. Grant RT (1963) Vasodilatation and body warming in the rat. J Physiol (Lond) 167:311-317.
129. Green AR (1998) Clomethiazo]e (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy. Pharmacol Ther 80:123-147.
130. Green AR, Cross AJ, and Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Psychopharmacology 119:247-260.
131. Green AR and Goodwin GM (1996) Ecstasy and neurodegeneration. Br Med J 312:1493.
132. Green AR and Grahame-Smith DG (1976) Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (Lond) 260:487-491.
133. Green AR, Hall JE, and Rees AR (1981) A behavioural and biochemical study in rats of 5-hydroxytryptamine agonists and antagonists with observations on structure-activity requirements for the agonists. Br J Pharmacol 73:703-720.
134. Green AR and Kelly PH (1976) Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-Dopa. Br J Pharmacol 57:141-147.
135. Green AR and McGregor IS (2002) On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology 164: 448-450.
136. Greer G and Strassman RJ (1985) Information on "Ecstasy." Am J Psychiatry 142:1391.
137. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319-395.
138. Grinspoon L and Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychotherapy 40:393-404.
139. Gudelsky GA (1996) Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J Neural Transm 102:1397-1404.
140. Gudelsky GA and Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
141. Gudelsky GA, Yamamoto BK, and Nash JF (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 264:325-330.
142. Gunn JA and Gurd MR (1940) The action of some amines related to adrenaline. Cyclohexylalkylamines. J Physiol (Lond) 97:453-470.
143. Gurtman CG, Morley KC, Li KM, Hunt GE, and McGregor IS (2002) Increased anxiety in rats after 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): association with serotonin depletion. Eur J Pharmacol 446:89-96.
144. Halliwell B and Kaur H (1997) Hydroxylation of salicylate and phenylalanine as assays for hydroxyl radicals: a cautionary note visited for the third time. Free Radic Res 27:239-244.
145. Halliwell B, Kaur H, and Ingelman-Sundberg M (1991) Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Radic Biol Med 10:439-441.
146. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, and Fleckenstein AE (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for toxicity. J Pharmacol Exp Ther 300:1093-1100.
147. Hardman HF, Haavik CO, and Seevers MH (1973) Relationship of the structure of mescaline and seven analogs to toxicity and behaviour in five species of laboratory animals. Toxicol Appl Pharmacol 25:299-309.
148. Harkin A, Connor TJ, Mulrooney J, Kelly JP, and Leonard BE (2001) Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sci 68:1367-1382.
149. Harris DS, Baggott M, Mendelson JH, Mendelson JE, and Jones RT (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 162:396-405.
150. Harro J (2002) Long-term partial 5-HT depletion: interference of anxiety and impulsivity? Psychopharmacology 164:433-434.
151. Harvey JA, McMaster SE, and Romano AG (1993) Methylenedioxyamphetamine: neurotoxic effects on serotonergic projections to brainstem nuclei in the rat. Brain Res 619:1-14.
152. Hashimoto K, Tomitaka S-H, Narita N, Minabe Y, and Iyo M (1997) Induction of Fos protein by 3,4-methylenedioxymethamphetamine (Ecstasy) in rat brain: regional differences in pharmacological manipulation. Addiction Biol 2:317-326.
153. Hatzidimitriou G, McCann UD, and Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with
154. Heffernan TM, Ling J, and Scholey AB (2001) Subjective ratings of prospective memory deficits in MDMA ("ecstasy") users. Hum Psychopharmacol Clin Exp 16:607-613.
155. Hegadoren KM, Baker GB, and Bourin M (1999) 3,4-methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539-553.
156. Heikkila RE, Cabbat FS, Manzino L, Babington RG, and Houlihan WJ (1981) Unexpected differences between mazindol and its homologs on biochemical and behavioral responses. J Pharmacol Exp Ther 217:745-749.
157. Hekmatpanah CR, McKenna DJ, and Peroutka SJ (1989) Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat. Neurosci Lett 104:178-182.
158. Heninger GR, Charney DS, and Sternberg DE (1984) Serotonergic function in depression. Prolactin responses to intravenous tryptophan in depressed patients and healthy subjects. Arch Gen Psychiatry 41:398-402.
159. Henry JA (1992) Ecstasy and the dance of death. Br Med J 305:5-6.
160. Henry JA, Jeffreys KJ, and Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387.
161. Hewitt KE and Green AR (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("Ecstasy") to rats. Neuropharmacology 33:1589-1595.
162. Hiramatsu M, Kumagai Y, Unger SE, and Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-527.
163. Hiramatsu M, Nabeshima T, Kameyama T, Maeda Y, and Cho AK (1989) The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol Biochem Behav 33:343-346.
164. Hubner CB, Bird M, Rassnick S, and Kornetsky C (1988) The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. Psychopharmacology 95: 49-51.
165. Hughes P and Dragunow M (1995) Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 47:133-178.
166. Imam SZ and Ali SF (2000) Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation. Brain Res 855:186-191.
167. Imam SZ, Crow JP, Newport GD, Islam F, Slikker W Jr, and Ali SF (1999) Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res 837:15-21.
168. Imam SZ, Newport GD, Itzhak Y, Cadet JL, Islam F, Slikker W Jr and Ali SF (2001) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem 76:745-749.
169. Insel TR, Battaglia G, Johannessen JN, Marra S, and De Souza EB (1989) 3,4-methylenedioxymethamphetamine ("Ecstasy") selectively destroys brain serotonin terminals in Rhesus monkeys. J Pharmacol Exp Ther 249:713-720.
170. Itzhak Y, Gandia C, Huang PL, and Ali SF (1998) Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J Pharmacol Exp Ther 284:1040-1047.
171. Itzhak Y, Martin JL, and Ali SF (2000) nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. Neuroreport 11:2943-2946.
172. Jacob JJ and Girault J-M (1979) 5-Hydroxytryptamine, in Body Temperature, Regulation, Drug Effects and Therapeutic Implications (Lomax P and Schonbaum E eds) pp 183-320, Marcel Dekker, Inc., New York.
173. 3H] dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276.
174. Jayanthi S, Ladenheim B, Andrews AM, and Cadet JL (1999) Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). Neuroscience 91:1379-1387.
175. Johnson M, Letter AA, Merchant K, Hanson GR, and Gibb JW (1988) Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J Pharmacol Exp Ther 244:977-982.
176. Johnson M, Mitros K, Stone DM, Zobrist R, Hanson GR, and Gibb JW (1992) Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 261:586-591.
177. Johnson EA, O'Callaghan JP, and Miller DB (2002b) Chronic treatment with supraphysiological levels of corticosterone enhances d-MDMA-induced dopaminergic neurotoxicity in the C57BL/6J female mouse. Brain Res 933:130-138.
178. Johnson EA, Sharp DS, and Miller DB (2000) Restraint as a stressor in mice: against the dopaminergic neurotoxicity of D-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection. Brain Res 875:107-118.
179. Johnson EA, Shvedova AA, Kisin E, O'Callaghan JP, Kommineni C, and Miller DB (2002a) d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res 933:150-163.
180. Kankaanpaa A, Meririnne E, Lillsunde P, and Seppala T (1998) The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 59:1003-1009.
181. 2A receptor antagonist MDL 100, 907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15:116-124.
182. Kehne JH, McCloskey TC, Taylor VL, Black CK, Fadayel GM, and Schmidt CJ (1992) Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. J Pharmacol Exp Ther 260:78-89.
183. Kehne JH, Padich RA, McCloskey TC, Taylor VL, and Schmidt CJ (1996b) 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology 124: 95-106.
184. Kelly PAT, Ritchie IM, Quate L, McBean DE, and Olverman HJ (2002) Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137:963-970.
185. Kil HY, Zhang J, and Piantadosi LA (1996) Brain temperature alters hydroxyl radical production during cerebral ischaemia/reperfusion in rats. J Cereb Blood Flow Metab 16:100-106.
186. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71:845-855.
187. Kish SJ, Furukawa Y, Ang L, Vorce SP, and Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 55:294-296.
188. Kleven MS, Woolverton WL, and Seiden LS (1989) Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. Brain Res 488:121-125.
189. Koch S and Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146.
190. Kokoshka JM, Vaughan RA, Hanson GR, and Fleckenstein AE (1998) Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol 361:269-275.
191. Krystal JH, Price LH, Opsahl C, Ricaurte GA, and Heninger GR (1992) Chronic 3,4-methylenedioxymethamphetamine (mdma) use - effects on mood and neuropsychological function. Am J Drug Alcohol Abuse 18:331-341.
192. Kumagai Y, Lin LY, Hiratsuka A, Narimatsu S, Suzuki T, Yamada H, Oguri K, Yoshimura H, and Cho AK (1994) Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol 45.359-365.
193. Lavelle A, Honner V, and Docherty JR (1999) Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br J Pharmacol 128:975-980.
194. Laverty R and Logan BJ (1990) Protection by MK 801 and other drugs of methylenedioxymethamphetamine (MDMA) neurotoxicity in rats and mice. Eur J Pharmacol 183:451-452.
195. Leonardi ET and Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231-238.
196. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, and Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276:855-865.
197. Liechti ME, Baumann C, Gamma A, and Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521.
198. Liechti ME, Geyer MA, Hell D, and Vollenweider FX (2001) Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24:240-252.
199. 2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23:396-404.
200. Liechti ME and Vollenweider FX (2000a) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ("Ecstasy") in healthy volunteers. J Psychopharmacol 14:269-274.
201. Liechti ME and Vollenweider FX (2000b) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10:289-295.
202. Liechti ME and Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Human Psychopharmacol 16:589-598.
203. Lim HK and Foltz RL (1988) In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol 1:370-378.
204. Lim HK and Foltz RL (1991a) In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques. Biol Mass Spectrom 20:677-686.
205. Lim HK and Foltz RL (1991b) Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chem Res Toxicol 4:626-632.
206. Lin HQ, Burden PM, Christie MJ, and Johnston GAR (1999) The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav 62:403-408.
207. Lin HQ, Jackson DM, Atrens DM, Christie MJ, and McGregor IS (1997) Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Res 744:351-357.
208. Lin LY, Kumagai Y, and Cho AK (1992) Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol 5:401-406.
209. Logan BJ, Laverty R, Sanderson WD, and Yee YB (1988) Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur J Pharmacol 152:227-234.
210. Lyon RA, Davis KH, and Titeler M (1987) 3H-DOB (4-bromo-2,5 dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194-199.
211. Malberg JE, Sabol KE, and Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278:258-267.
212. Malberg JE and Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18:5086-5094.
213. Maldonado E and Navarro JF (2001) MDMA ("ecstasy") exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol Res 44:27-31.
214. Malpass A, White JM, Irvine RJ, Somogyi AA, and Bochner F (1999) Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 64:29-34.
215. Mamounas LA, Mullen CA, O'Hearn E, and Molliver ME (1991) Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314:558-586.
216. Mansbach RS, Braff DL, and Geyer MA (1989) Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat. Eur J Pharmacol 167:49-55.
217. Marek GJ, Vosmer G, and Seiden LS (1990) The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res 516:1-7.
218. Marsh JC, Abboudi ZH, Gibson FM, Scopes J, Daly S, O'Shaunnessy DF, Baughan AS, and Gordon-Smith EC (1994) Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ("Ecstasy"). Br J Haematol 88:281-285.
219. Marston HM, Reid ME, Lawrence JA, Olverman HJ, and Butcher SP (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology 144:67-76.
220. Martinez DL and Geyer MA (1997) Characterization of the disruptions of prepulse inhibition and habituation of startle induced by α-ethyltryptamine. Neuropsychopharmacology 16:246-255.
221. Mas M, Farré M, de la Torre R, Roset PN, Ortuño J, Segura J, and Camí J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145.
222. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol Lett (Shannon) 112-113:133-142.
223. Mayerhofer A, Kovar K, and Schmidt WJ (2001) Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats. Neurosci Lett 308:99-102.
224. 2C receptors. Psychopharmacology 123:333-339.
225. McCann UD, Eligulashvili V, Mertl M, Murphy DL, and Ricaurte GA (1999a) Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147:56-65.
226. McCann UD, Mertl M, Eligulashvili V, and Ricaurte GA (1999b) Cognitive performance in (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology 143:417-425.
227. McCann UD and Ricaurte GA (1991) Lasting neuropsychiatric sequelae of (±)methylenedioxymethamphetamine ("Ecstasy") in recreational users. J Clin Psychopharmacol 11:302-305.
228. McCann UD and Ricaurte GA (1992) MDMA ("Ecstasy") and panic disorder: induction by a single dose. Biol Psychiatry 32:950-953.
229. McCann UD and Ricaurte GA (1993) Reinforcing subjective effects of (+/-)-3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharmacol 13:214-217.
230. McCann UD and Ricaurte GA (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24:333-336.
231. McCann UD, Ridenour A, Shaham Y, and Ricaurte GA (1994) Serotonin neurotoxiicity after (±)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10:129-138.
232. McCann UD, Slate SO, and Ricaurte GA (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Drug Safety 15:107-115.
233. McCann UD, Szabo Z, Scheffel U, Dannals RF, and Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352:1433-1437.
234. 1B/1D receptors. J Pharmacol Exp Ther 290:965-973.
235. McDaid J and Docherty JR (2001) Vascular actions of MDMA involve alphal and alpha2-adrenoceptors in the anaesthetized rat. Br J Pharmacol 139:429-437.
236. McGuire P (2000) Long term psychiatric and cognitive effects of MDMA use. Toxicol Lett (Shannon) 112-113:153-156.
237. McGuire PK, Cope H, and Fahy TA (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy"). Br J Psychiatry 165:391-395.
238. McGuire P and Fahy T (1991) Chronic paranoid psychosis after misuse of MDMA ("ecstasy"). Br Med J 302:697.
239. McGuire P, Jones P, and Murray R (1993) Psychiatric symptoms in cannabis users. Br J Psychiatry 163:698.
240. McKenna DJ and Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). J Neurochem 54:14-22.
241. McNamara MG, Kelly JP, and Leonard BE (1995) Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol Biochem Behav 52:479-484.
242. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, and Green AR (2002a) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA "ecstasy") to rats. Br J Pharmacol 135:170-180.
243. Mechan AO, Moran PM, Elliott JM, Young AMJ, Joseph MH, and Green AR (2002b) A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA: "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology 159:167-175.
244. Mechan AO, Moran PM, Elliott JM, Young AMJ, Joseph MH, and Green AR (2002c) A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters and their response to diazepam. Psychopharmacology 159:188-195.
245. Mechan AO, O'Shea E, Elliott JM, Colado MI, and Green AR (2001) A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation. Psychopharmacology 155:413-418.
246. Meltzer HY and Maes M (1995a) Pindolol pretreatment blocks stimulation by metachlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Res 58:89-98.
247. Meltzer HY and Maes M (1995b) Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biol Psychiatry 38:310-318.
248. Miller RT, Lau SS, and Monks TJ (1995) Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem Res Toxicol 8:634-641.
249. Miller RT, Lau SS, and Monks TJ (1996) Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin and norepinephrine concentrations in male Sprague-Dawley rats. Chem Res Toxicol 9:457-465.
250. Miller RT, Lau SS, and Monks TJ (1997) 2, 5-bis-(glutathion-S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-180.
251. Miller DB and O'Callaghan JP (1994) Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:752-760.
252. Miller DB and O'Callaghan JP (1995) The role of temperature, stress and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol 11:177-192.
253. Milroy CM, Clark JC, and Forrest ARW (1996) Pathology of deaths associated with ecstasy and "Eve" misuse. J Clin Pathol (London) 49:149-153.
254. Milton AS (1977) The hypothalamus and the pharmacology of thermoregulation, in Pharmacology of the Hypothalamus (Cox B, Morris ID, and Weston AH eds) The Macmillan Press Ltd., London.
255. Mohaghegh RA, Soulsby ME, Skinner RD, and Kennedy RH (1997) The interaction between the central and peripheral nervous systems in mediating the thermic effect of methamphetamine. Ann NY Acad Sci 813:197-203.
256. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, and Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600:640-661.
257. Molliver ME, O'Hearn E, Battaglia G, and De Souza ER (1986) Direct intracerebral administration of MDMA and MDA does not produce serotonin neurotoxicity. Soc Neurosci Abstr 12:1234.
258. Moorman JM and Leslie RA (1996) P-chloroamphetamine induces c-fos in rat brain: a study of serotonin2A/2C receptor function. Neuroscience 72:129-139.
259. Mordenti J and Chappell W (1989) The use of interspecies scaling in toxicokinetics, in Toxicokinetics and New Drug Development (Yacogi A, Kelly J, and Batra V eds) pp 42-96, Pergamon Press, New York.
260. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology 141:30-36.
261. Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230-248.
262. Morgan MJ, McFie L, Fleetwood LH, and Robinson JA (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159:294-303.
263. Mørland J (2000) Toxicity of drug abuse - amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. Toxicol Lett (Shannon) 112-113:147-152.
264. Morley KC, Gallate JE, Hunt GE, Mallet PE, and McGregor IS (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). Eur J Pharmacol 433:91-99.
265. Morley KC and McGregor IS (2000) (±)-3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") increases social interaction in rats. Eur J Pharmacol 408:41-49.
266. Morton AJ, Hickey MA, and Dean LC (2001) Methamphetamine toxicity in mice is potentiated by exposure to loud music. Neuroreport 12:3277-3281.
267. Murphy JEJ, Flynn JJ, Cannon DM, Guiry PJ, McCormack P, Baird AW, McBean GJ, and Keenan AK (2002) In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 444:61-67.
268. Murray TK, Williams JL, Misra A, Colado MI, and Green AR (1996) The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine. Neuropharmacology 35:1615-1620.
269. Myers RD (1981) Serotonin and thermoregulation: old and new views. J Physiol (Lond) 77:505-513.
270. Nash JF (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47:2401-2408.
271. Nash JF and Brodkin J (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259:820-825.
272. Nash JF, Meltzer HY, and Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245:873-879.
273. Nash JF and Nichols DE (1991) Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur J Pharmacol 200:53-58.
274. Nash JF, Roth BL, Brodkin JD, Nichols DE, and Gudelsky GA (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177:111-115.
275. Nash JF and Yamamoto BK (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581:237-243.
276. Newton RA, Phipps SL, Flanigan TP, Newberry NR, Carey JE, Kumar C, McDonald B, Chen C, and Elliott JM (1996) Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. J Neurochem 67:2521-2531.
277. National Institute on Drug Abuse (NIDA) (2002). Monitoring the Future. National Survey Results on Drug Use, 1975-2001. Volume I: Secondary School Students. NIH Publication 02-5106. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
278. Nixdorf WI, Burrows KB, Gudelsky GA, and Yamamoto BK (2001) Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J Neurochem 77:647-654.
279. Nobler MS, Mann JJ, and Sackeim HA (1999) Serotonin, cerebral blood flow and cerebral metabolic rate in geriatric major depression and normal aging. Brain Res Rev 30:250-263.
280. Obradovic T, Imel KM, and White SR (1998) Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin. Brain Res 785:1-9.
281. O'Cain PA, Hletko SB, Ogden BA, and Varner KJ (2000) Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav 70:141-148.
282. O'Callaghan JP and Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
283. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, and Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803.
284. O'Loinsigh ED, Boland G, Kelly JP, and O'Boyle KM (2001) Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuropsychopharmacol Biol Psychiatry 25:621-638.
285. O'Shea E, Easton N, Fry JR, Green AR, and Marsden CA (2002) Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia. J Neurochem 81:686-695.
286. O'Shea E, Esteban B, Camarero J, Green AR, and Colado MI (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ("ecstasy") on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65-74.
287. O'Shea E, Granados R, Esteban B, Colado MI, and Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ("ecstasy"). Neuropharmacology 37:919-926.
288. 1A receptor involvement in the control of prolactin secretion in man. Psychopharmacology 119:311-314.
289. Paris JM and Cunningham KA (1991) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res Bull 28:115-119.
290. Parrott AC and Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139:261-268.
291. Parrott AC, Lees A, Garnham NJ, Jones M, and Wesnes K (1998) Cognitive performance in recreational users of MDMA or ecstasy: evidence for memory deficits. J Psychopharmacol 12:79-83.
292. Parrott AC, Milani RM, Parmar R, and Turner JJD (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77-82.
293. Parrott AC, Sisk E, and Turner JJD (2000) Psychobiological problems in heavy "ecstasy" (MDMA) poly-drug users. Drug Alcohol Depend 60:105-110.
294. Parrott AC and Stuart M (1997) Ecstasy (MDMA), amphetamine and LSD: comparative mood profiles in recreational poly-drug users. Human Psychopharmacol 12:501-504.
295. Peroutka SJ (1987) Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") on an undergraduate campus. N Engl J Med 317:1542-1543.
296. Peroutka SJ, Newman H, and Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273-277.
297. Piercey MF, Lum JT, and Palmer JR (1990) Effects of MDMA ("ecstasy") on firing rates of serotonergic, dopaminergic and noradrenergic neurons in the rat. Brain Res 526:203-206.
298. Price LH, Ricaurte GA, Krystal JH, and Heninger GR (1989) Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen Psychiatry 46:20-22.
299. Quate L, McBean DE, Ritchie IM, Olverman HJ, and Kelly PAT (2003) Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the rat. Br J Pharmacol 138:197P.
300. 2A/D-adrenoceptor knockout mice. Eur J Pharmacol 423:223-228.
301. Rattray M (1991) Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem 26:77-87.
302. Reid LD, Hubbell CL, Tsai J, Fishkin MD, and Amendola CA (1996) Naltrindole, a δ-opioid antagonist, blocks MDMA's ability to enhance pressing for rewarding brain stimulation. Pharmacol Biochem Behav 53:477-480.
303. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Boudewijn Gunning W, den Heeten GJ, and van den Brink W (2001) Effects of dose, sex and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurones. Lancet 358:1864-1869.
304. Reneman L, Booij J, Habraken JBA, De Bruin K, Hatzidimitriou G, Den Heeten GJ, and Ricaurte GA (2002d) Validity of [I-123] beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46:199-205.
305. 123I]β-CIT SPECT study - preliminary report. Psychopharmacology 159:335-340.
306. Reneman L, Booij J, Schmand B, van den Brink W, and Gunning B (2000b) Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 148:322-324.
307. 2A receptors in rat and human brain. Neuropsychopharmacology 26:387-396.
308. Reneman L, Habraken JB, Majoie CB, Booij J, and den Heeten GJ (2000a) MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol 21:1001-1007.
309. Reneman L, Majoie CBLM, Flick H, and den Heeten GJ (2002c) Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (ecstasy) users: preliminary results. Am J Neuroradiol 23:231-237.
310. Ricaurte G, Bryan G, Strauss L, Seiden L, and Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science (Wash DC) 229:986-988.
311. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, and Langston JW (1988a) 5-hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 474:2359-2363.
312. Ricaurte GA, DeLanney LE, Irwin I, and Langston JW (1988c) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446:165-168.
313. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, and Langston JW (1988b) (±)-3,4-methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. J Am Med Assoc 260: 51-55.
314. Ricaurte GA, Martello AL, Katz JL, and Martello MB (1992) Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261:616-622.
315. Ricaurte GA and McCann UD (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 648:371-382.
316. Ricaurte GA, McCann UD, Szabo Z, and Scheffel U (2000) Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Toxicol Lett (Shannon) 112-113:143-146.
317. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, and McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a single recreational dose regimen of MDMA ("Ecstasy"). Science (Wash DC) 297:2260-2263.
318. Rodgers J (2000) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151:19-24.
319. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
320. Rouillard C, Bovetto S, Gervais J, and Richard D (1996) Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Brain Res Mol Brain Res 37:105-115.
321. Rowland NE, Kalehua AN, Li BH, Semple-Rowland SL, and Streit WJ (1993) Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain Res 624:35-43.
322. Rutty GN and Milroy CM (1997) The pathology of the ring-substituted amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Pathol 181:255-256.
323. Sabol KE, Lew R, Richards JB, Vosmer GL, and Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 276:846-854.
324. Sabol KE and Seiden LS (1998) Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res 806:69-78.
325. 2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98:495-499.
326. Salansky N, Fedotchev A, and Bondar A (1998) Responses of the nervous system to low frequency stimulation and EEG rhythms: clinical implications. Neurosci Biobehav Rev 22:395-409.
327. 2A receptors in rat thermoregulatory mechanisms. Pharmacol Toxicol 82:122-127.
328. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, and Colado MI (2001) The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ("ecstasy")-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134:46-57.
329. Sanchez V, Camarero J, O'Shea E, Green AR, and Colado MI (2003) Differential effect of dietary selenium on the long term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 44:449-461.
330. Saunders N (1996) No evidence of neurotoxicity exists. Br Med J 313:423.
331. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, and Ricaurte GA (1993) Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264:1484-1491.
332. 1B receptor. Psychopharmacology 141:154-161.
333. 2 receptors. Neuropharmacology 31:881-893.
334. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, and Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse 29:183-192.
335. Schifano F (1991) Chronic atypical psychosis associated with MDMA ("ecstasy") abuse. Lancet 338:1335.
336. Schmidt CJ (1987a) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7.
337. Schmidt CJ (1987b) Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol 136:81-88.
338. 2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 255:478-483.
339. 2 receptors. Brain Res 529:85-90.
340. Schmidt CJ, Black CK, and Taylor VL (1990c) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol 181:59-70.
341. Schmidt CJ and Kehne JH (1990) Neurotoxicity of MDMA: neurochemical effects. Ann NY Acad Sci 600:665-681.
342. Schmidt CJ, Levin JA, and Lovenberg W (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36:747-755.
343. Schmidt CJ and Taylor VL (1987) Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36:4095-4102.
344. Schmidt CJ and Taylor VL (1988) Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur J Pharmacol 156:121-131.
345. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-DOPA. J Pharmacol Exp Ther 256:230-235.
346. Schmidt CJ, Wu L, and Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124:175-178.
347. Screaton GR, Cairns HS, Sarner M, Singer M, Thrasher A, and Cohen SL (1992) Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 339: 677-678.
348. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, and Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 175:63-69.
349. Shankaran M and Gudelsky GA (1998) Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 61:361-366.
350. Shankaran M and Gudelsky GA (1999) A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology 147:66-72.
351. Shankaran M, Yamamoto BK, and Gudelsky GA (1999a) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 385:103-110.
352. Shankaran M, Yamamoto BK, and Gudelsky GA (1999b) Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem 72:2516-2522.
353. Shankaran M, Yamamoto BK, and Gudelsky GA (2001) Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40:55-64.
354. Shimizu N, Take S, Hori T, and Oomura Y (1992) In vivo measurement of hypothalamic serotonin release by intracerebral microdialysis: significant enhancement by immobilization stress in rats. Brain Res Bull 28:727-734.
355. Shirayama Y, Hashimoto K, Iyo M, Watanabe K, Higuchi T, and Minabe Y (2000) 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation. Eur J Pharmacol 402:215-222.
356. Shulgin AT and Nichols DE (1978) Characterization of three new psychomimetics, in The Psychopharmacology of Hallucinogens (Stillman RC and Willette RE eds), Pergamon Press, Oxford.
357. Simpson DL and Rumack BH (1981) Methylenedioxymethamphetamine. Clinical description of overdose, death and review of pharmacology. Arch Intern Med 141:1507-1509.
358. Slikker W Jr, Ali SF, Scallet AC, Frith CH, Newport GD, and Bailey JR (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 96:448-457.
359. Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, and Scalzo FM (1989) Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10:529-542.
360. Solowij N, Hall W, and Lee N (1992) Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. Br J Addict 87:1161-1172.
361. Soubrie P (1986) Reconciling the role of central serotonin neurons in human and animal behaviour. Behav Brain Sci 9:319-364.
362. Spanos LJ and Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32:835-840.
363. Sprague JE, Everman SL, and Nichols DE (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19:427-442.
364. Sprague JE and Nichols DE (1995) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273:667-673.
365. Steele TD, Nichols DE, and Yim GK (1987) Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36:2297-2303.
366. Stein DJ and Rink J (1999) Effects of "Ecstasy" blocked by serotonin reuptake inhibitors. J Clin Psychiatry 60:485.
367. Stephenson CP, Hunt GE, Topple AN, and McGregor IS (1999) The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain. Neuroscience 92:1011-1023.
368. Steranka LR and Rhind AW (1987) Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. Eur J Pharmacol 133:191-197.
369. Steward O and Worley PF (2001) A cellular mechanism for targeting newly synthesized mRNAs to synaptic sites on dendrites. Proc Natl Acad Sci USA 98:7062-7068.
370. St. Omer VEV, Ali SF, Holson RR, Duhart HM, Scalzo FM, and Slikker JW (1991) Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicol Teratol 13:13-20.
371. Stone DM, Hanson GR, and Gibb JW (1987a) Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26:1657-1661.
372. Stone DM, Johnson M, Hanson GR, and Gibb JW (1987b) A comparison of the neurotoxic potential of methylenedioxymethamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol 134:245-248.
373. Stone DM, Johnson M, Hanson GR, and Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247:79-87.
374. Stone DM, Johnson M, Hanson GR, and Gibb JW (1989) Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulphydryl sites. Eur J Pharmacol 172:93-97.
375. Stone DM, Merchant KM, Hanson GR, and Gibb JW (1987c) Immediate and long term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683.
376. Stone DM, Stahl DC, Hanson GR, and Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128:41-48.
377. Strote J, Lee JE, and Wechsler H (2002) Increasing MDMA use among college students: results of a national survey. J Adolesc Health 30:64-72.
378. Sugimoto Y, Ohkura M, Inoue K, and Yamada J (2001) Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. Eur J Pharmacol 430:265-268.
379. 11-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43:678-692.
380. 11C]McN5652. J Cereb Blood Flow Metab 15:798-805.
381. Taffe MA, Weed MR, David S, Huitrón-Resendiz S, Schroeder R, Parsons LH, Henriksen SJ, and Gold LH (2001) Functional consequences of repeated (±)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology 24:230-239.
382. 1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamine)tetraline in the rat. Eur J Pharmacol 76:81-85.
383. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TYY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
384. Varela-Rey M, Montiel-Duarte C, Beitia G, Cenarruzabeitia E, and Iraburu MJ (1999) 3,4-methylenedioxymethamphetamine ("Ecstasy") stimulates the expression of α1 (I) procollagen mRNA in hepatic stellate cells. Biochem Biophys Res Commun 259:678-682.
385. Verheyden SL, Hadfield J, Calin T, and Curran HV (2002) Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine "ecstasy") on mood: evidence of gender differences. Psychopharmacology 161:23-31.
386. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJM, de Bruin D, Van de Wijngaart G, Van Gerven JMA, et al. (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153:196-202.
387. Vingerboets FJG, Snow BJ, Tetrud JW, Langston JW, Schulzer M, and Calne DB (1994) Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 36:765-770.
388. Vollenweider FX, Gamma A, Liechti M, and Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19:241-251.
389. Vollenweider FX, Jones RT, and Baggott MJ (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24:461-463.
390. Vollenweider FX, Remensberger S, Hell D, and Geyer MA (1999) Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology 143:365-372.
391. Walderhaug E, Lunde H, Nordvik JE, Landrø NI, Regsum H, and Magnusson A (2002) Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. Psychopharmacology 164:385-391.
392. Wallace TL, Gudelsky GA, and Vorhees CV (2001) Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Psychopharmacology 153:321-326.
393. Wareing M, Fisk JE, and Murphy PN (2000) Working memory deficits in current and previous users of MDMA (Ecstasy). Br J Psychol 91:181-188.
394. Webb E, Ashton CH, Kelly P, and Kamali F (1996) Alcohol and drug use in UK university students. Lancet 348:922-925.
395. Whitaker-Azmitia PM and Aronson TA (1989) "Ecstasy" (MDMA)-induced panic. Am J Psychiatry 146:119.
396. Wilkerson G and London ED (1989) Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat. Neuropharmacology 28:1129-1138.
397. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, and Strang J (1997) Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 44:87-94.
398. Wilson MA and Molliver ME (1994) Microglial response to degeneration of serotonergic axon terminals. Glia 11:18-34.
399. Wilson MA, Ricaurte GA, and Molliver ME (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28:121-137.
400. Winsauer PJ, McCann UD, Yuan J, Delatte MS, Stevenson MW, Ricaurte GA, and Moerschbaecher JM (2002) Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology 159:388-396.
401. Winstock AR, Griffiths P, and Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64:9-17.
402. Wolf HH and Bunce ME (1973) Hyperthermia and the amphetamine aggregation phenomenon: absence of a causal relation. J Pharm Pharmacol 25:425-427.
403. Yamamoto BK and Spanos LJ (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148:195-203.
404. Yamamoto BK, Nash JF, and Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and γ-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273:1063-1070.
405. Yamawaki S, Lai H, and Horita A (1983) Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine. J Pharmacol Exp Ther 227:383-388.
406. Yeh SY (1997) Effects of salicylate on 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Pharmacol Biochem Behav 58:701-708.
407. Yeh SY (1999) N-tert-butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse 31:169-177.
408. Yeh SY and Hsu FL (1991) The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats. Pharmacol Biochem Behav 39:787-790.
409. Yuan J, Callahan BY, McCann UD, and Ricaurte GA (2001) Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem 77:1338-1347.
410. Yuan J, Cord BJ, McCann UD, Callahan T, and Ricaurte GA (2002) Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem 80:960-969.
411. 3H]methylenedioxyamphetamine: characterization suggests the presence of a factor responsible for maintaining sequestration. J Neurochem 54:195-204.
412. Zhao Z, Castagnoli N Jr, Ricaurte GA, Steele T, and Martello M (1992) Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl]propane [(methylenedioxy)methamphetamine]. Chem Res Toxicol 5:89-94.
413. Zheng Y and Laverty R (1998) Role of brain nitric oxide in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Brain Res 795:257-263.
414. Ziporyn T (1986) A growing industry and menace: makeshift laboratory's designer drugs. J Am Med Assoc 256:3061-3063.